# PRODUCT INFORMATION



## Abiraterone

Item No. 9002768


CAS Registry No.: 154229-19-3

Formal Name: (3β)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol

Synonym: CB-7598 MF: C<sub>24</sub>H<sub>31</sub>NO FW: 349.5 **Purity:** ≥98%  $\lambda_{max}$ : 254 nm A crystalline solid UV/Vis.: Supplied as:

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



# **Laboratory Procedures**

Abiraterone is supplied as a crystalline solid. A stock solution may be made by dissolving the abiraterone in the solvent of choice, which should be purged with an inert gas. Abiraterone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of abiraterone in ethanol and DMF is approximately 15 mg/ml and approximately 1 mg/ml in DMSO.

Abiraterone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, abiraterone should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Abiraterone has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

Abiraterone is an inhibitor of the cytochrome P450 (CYP) isoform CYP17A1 (IC<sub>50</sub>s = 0.0029 and 0.004  $\mu$ M for the 17,20-lyase and  $17\alpha$ -hydroxylase activities, respectively) and active metabolite of abiraterone acetate (Item No. 15148).<sup>1,2</sup> It is formed from abiraterone acetate by arylacetamide deacetylase.<sup>3</sup> Abiraterone is selective for CYP17A1 over aromatase and  $5\alpha$ -reductase ( $IC_{50}$ S = >20 and >50  $\mu$ M, respectively).

### References

- 1. Potter, G.A., Barrie, S.E., Jarman, M., et al. Novel steroidal inhibitors of human cytochrome P450<sub>17a</sub>  $(17\alpha$ -hydroxylase- $C_{17.20}$ -lyase): Potential agents for the treatment of prostatic cancer. J. Med. Chem. **38(13)**, 2463-2471 (1995).
- 2. Barrie, S.E., Potter, G.A., Goddard, P.M., et al. Pharmacology of novel steroidal inhibitors of cytochrome P450<sub>17a</sub> (17a-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol. 50(5-6), 267-273 (1994).
- 3. Sakai, Y., Fukami, T., Nagaoka, M., et al. Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans. Life Sci. 284, 119896 (2021).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/13/2022

### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM